Fatty Acid Oxidation and Malonyl-CoA Decarboxylase in the Vascular Remodeling of Pulmonary Hypertension
- 11 August 2010
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 2 (44), 44ra58
- https://doi.org/10.1126/scitranslmed.3001327
Abstract
Pulmonary arterial hypertension is caused by excessive growth of vascular cells that eventually obliterate the pulmonary arterial lumen, causing right ventricular failure and premature death. Despite some available treatments, its prognosis remains poor, and the cause of the vascular remodeling remains unknown. The vascular smooth muscle cells that proliferate during pulmonary arterial hypertension are characterized by mitochondrial hyperpolarization, activation of the transcription factor NFAT (nuclear factor of activated T cells), and down-regulation of the voltage-gated potassium channel Kv1.5, all of which suppress apoptosis. We found that mice lacking the gene for the metabolic enzyme malonyl–coenzyme A (CoA) decarboxylase (MCD) do not show pulmonary vasoconstriction during exposure to acute hypoxia and do not develop pulmonary arterial hypertension during chronic hypoxia but have an otherwise normal phenotype. The lack of MCD results in an inhibition of fatty acid oxidation, which in turn promotes glucose oxidation and prevents the shift in metabolism toward glycolysis in the vascular media, which drives the development of pulmonary arterial hypertension in wild-type mice. Clinically used metabolic modulators that mimic the lack of MCD and its metabolic effects normalize the mitochondrial-NFAT-Kv1.5 defects and the resistance to apoptosis in the proliferated smooth muscle cells, reversing the pulmonary hypertension induced by hypoxia or monocrotaline in mice and rats, respectively. This study of fatty acid oxidation and MCD identifies a critical role for metabolism in both the normal pulmonary circulation (hypoxic pulmonary vasoconstriction) and pulmonary hypertension, pointing to several potential therapeutic targets for the treatment of this deadly disease.Keywords
This publication has 53 references indexed in Scilit:
- Basic Science of Pulmonary Arterial Hypertension for CliniciansCell Metabolism, 2010
- PPARγ Activation: A Potential Treatment For Pulmonary HypertensionScience Translational Medicine, 2009
- Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nef-infected macaquesAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- Understanding the Warburg Effect: The Metabolic Requirements of Cell ProliferationScience, 2009
- The metabolic basis of vascular oxygen sensing: diversity, compartmentalization, and lessons from cancerAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescueHuman Molecular Genetics, 2008
- The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targetedProceedings of the National Academy of Sciences, 2007
- Cell-Permeating α-Ketoglutarate Derivatives Alleviate Pseudohypoxia in Succinate Dehydrogenase-Deficient CellsMolecular and Cellular Biology, 2007
- Alterations of cellular bioenergetics in pulmonary artery endothelial cellsProceedings of the National Academy of Sciences, 2007
- Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST–segment elevation myocardial infarction: Appropriate interpretation of the guidelinesAmerican Heart Journal, 2003